125 related articles for article (PubMed ID: 12971973)
1. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.
Ryu SH; Chung YH; Choi MH; Kim JA; Shin JW; Jang MK; Park NH; Lee HC; Lee YS; Suh DJ
J Hepatol; 2003 Oct; 39(4):614-9. PubMed ID: 12971973
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
[TBL] [Abstract][Full Text] [Related]
3. Determinants for sustained HBeAg response to lamivudine therapy.
Chien RN; Yeh CT; Tsai SL; Chu CM; Liaw YF
Hepatology; 2003 Nov; 38(5):1267-73. PubMed ID: 14578866
[TBL] [Abstract][Full Text] [Related]
4. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
[TBL] [Abstract][Full Text] [Related]
5. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
[TBL] [Abstract][Full Text] [Related]
6. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
[TBL] [Abstract][Full Text] [Related]
7. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
8. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion.
Lee KM; Cho SW; Kim SW; Kim HJ; Hahm KB; Kim JH
J Viral Hepat; 2002 May; 9(3):208-12. PubMed ID: 12010509
[TBL] [Abstract][Full Text] [Related]
9. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.
Lee HC; Suh DJ; Ryu SH; Kim H; Shin JW; Lim YS; Chung YH; Lee YS
Gut; 2003 Dec; 52(12):1779-83. PubMed ID: 14633962
[TBL] [Abstract][Full Text] [Related]
10. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan.
Huang YH; Wu JC; Chang TT; Sheen IJ; Lee PC; Huo TI; Su CW; Wang YJ; Chang FY; Lee SD
J Viral Hepat; 2003 Jul; 10(4):277-84. PubMed ID: 12823594
[TBL] [Abstract][Full Text] [Related]
11. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B.
Liu CJ; Huang WL; Chen PJ; Lai MY; Kao JH; Chen DS
World J Gastroenterol; 2004 Dec; 10(24):3574-8. PubMed ID: 15534909
[TBL] [Abstract][Full Text] [Related]
12. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation.
Lee CM; Ong GY; Lu SN; Wang JH; Liao CA; Tung HD; Chen TM; Changchien CS
J Hepatol; 2002 Nov; 37(5):669-74. PubMed ID: 12399235
[TBL] [Abstract][Full Text] [Related]
13. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion.
Yoon SK; Jang JW; Kim CW; Bae SH; Choi JY; Choi SW; Lee YS; Lee CD; Chung KW; Sun HS; Kim BS
Intervirology; 2005; 48(6):341-9. PubMed ID: 16024938
[TBL] [Abstract][Full Text] [Related]
15. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.
Lee HW; Lee HJ; Hwang JS; Sohn JH; Jang JY; Han KJ; Park JY; Kim DY; Ahn SH; Paik YH; Lee CK; Lee KS; Chon CY; Han KH
Hepatology; 2010 Feb; 51(2):415-21. PubMed ID: 19902424
[TBL] [Abstract][Full Text] [Related]
16. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.
Alexander G; Baba CS; Chetri K; Negi TS; Choudhuri G
BMC Gastroenterol; 2005 Sep; 5():29. PubMed ID: 16164746
[TBL] [Abstract][Full Text] [Related]
17. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
van Nunen AB; Hansen BE; Suh DJ; Löhr HF; Chemello L; Fontaine H; Heathcote J; Song BC; Janssen HL; de Man RA; Schalm SW
Gut; 2003 Mar; 52(3):420-4. PubMed ID: 12584227
[TBL] [Abstract][Full Text] [Related]
18. Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation.
Kim JH; Lee SJ; Joo MK; Kim CH; Choi JH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Dig Dis Sci; 2009 Jul; 54(7):1572-7. PubMed ID: 18975080
[TBL] [Abstract][Full Text] [Related]
19. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
Cho SW; Hahm KB; Kim JH
Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
[TBL] [Abstract][Full Text] [Related]
20. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
